Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of GIST patients treated with delayed imatinib therapy.
Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, Vranic S, Kopric D, Iljazovic E, Todorovic Barbuscia J, Kozaric M, Ibisevic N, Keskic L, Kurtovic S. Kurtovic-Kozaric A, et al. Among authors: beslija s. Eur J Cancer. 2017 Jun;78:118-121. doi: 10.1016/j.ejca.2017.03.024. Epub 2017 Apr 21. Eur J Cancer. 2017. PMID: 28437709 No abstract available.
Letter to the Editor/Response.
Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, Vranic S. Imamovic D, et al. Among authors: beslija s. Breast J. 2019 May;25(3):569. doi: 10.1111/tbj.13284. Epub 2019 Apr 13. Breast J. 2019. PMID: 30980590 No abstract available.
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, Vranić S, Mustedanagić-Mujanović J, Skenderi F, Rakita I, Guzijan A, Koprić D, Humačkić A, Trokić D, Alidžanović J, Efendić A, Šišić I, Drljević H, Bešlagić V, Babić B, Pašić A, Ramić A, Mikić D, Guzin Z, Karan D, Buhovac T, Miletić D, Šečić S, Đozić Šahmić A, Mujbegović L, Kubura A, Burina M, Lalović N, Dukić N, Vladičić Mašić J, Ćuk M, Stanušić R. Bešlija S, et al. Bosn J Basic Med Sci. 2021 Apr 1;21(2):120-135. doi: 10.17305/bjbms.2020.4846. Bosn J Basic Med Sci. 2021. PMID: 32415816 Free PMC article.
Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 among cancer patients in Bosnia and Herzegovina: A single-center cross-sectional study.
Cerić T, Sokolović E, Pašić A, Borovac-Gurda E, Smajlbegović V, Hasanbegović B, Bičakčić Filipović E, Kapisazović E, Sokolović S, Bešlija S. Cerić T, et al. Among authors: beslija s. Bosn J Basic Med Sci. 2022 Sep 16;22(5):833-842. doi: 10.17305/bjbms.2021.7134. Bosn J Basic Med Sci. 2022. PMID: 35427467 Free PMC article.
Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers.
Miletić D, Kraljević M, Sokolović E, Soče M, Milović-Kovačević M, Bobić S, Cerić T, Pleština S, Bešlija S, Marijanović I. Miletić D, et al. Among authors: beslija s. Med Sci Monit. 2023 Jun 2;29:e940356. doi: 10.12659/MSM.940356. Med Sci Monit. 2023. PMID: 37264567 Free PMC article.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Lang I, et al. Among authors: beslija s. Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10. Lancet Oncol. 2013. PMID: 23312888 Clinical Trial.
43 results